Mário Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mário Pinto has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A.S. Santos
Cystic Fibrosis Reference Center, Santa Marta Hospital, São José Local Health Unit
1 shared publicationAntónio Miguel
Interventional Pulmonology Unit, Pulmonology Department, University Hospital Center of Central Lisbon, Rua de Santa Marta 50, Lisbon, 1169-024, Portugal
1 shared publicationDionísio Maia
Interventional Pulmonology Unit, Pulmonology Department, University Hospital Center of Central Lisbon, Rua de Santa Marta 50, Lisbon, 1169-024, Portugal
1 shared publication- Fernando Nolasco
Transplant Unit, Curry Cabral Hospital, Central Lisbon University Hospital Center, Nova Medical School, Nova University, Lisbon, Portugal
1 shared publication - Helena Sousa
Hospital Curry Cabral, Portugal
1 shared publication - Joana Marques
Serviço de Nefrologia, Unidade Local de Saúde São José
1 shared publication
Latest Publications
- Open Access
- 30 September 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (5) , 485-487
Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants
- 30 September 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (5) , 485-487
Open AccessEfficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants
- Open Access
- 14 January 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 43, 100627
Endobronchial amphotericin B to treat hemoptysis in an inoperable patient with aspergillosis
- 14 January 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 43, 100627
Open AccessEndobronchial amphotericin B to treat hemoptysis in an inoperable patient with aspergillosis
- Open Access
Journal club
Community-acquired pneumonia remains a major cause of morbidity and mortality globally, with overall in-hospital mortality rates of 10%–12%, reaching 30% for patients requiring mechanical ventilation. Although corticosteroids have shown benefits in these patients, the impact on survival remains unproven. Dequin and colleagues (N Engl J Med 2023;388:1931) performed a multicentre trial in French critical care units to evaluate the effect of early hydrocortisone treatment on the mortality of patients with severe pneumonia treated in the ICU. Pneumonia severity criteria required for enrolment were: mechanical ventilation with positive end-expiratory pressure of at least 5 cmH2O; arterial oxygen tension/fractional inspired oxygen (FiO2) ratio lower than 300 (with FiO2≥50%); and Pulmonary Severity Index greater than 130. A notable exclusion criterion was septic shock. Of 5948 screened, 800 adult patients with pneumonia were randomised to either intravenous hydrocortisone (200 mg for 4 or 7 days; dependent on clinical progress followed by a tapering dose over up to 14 days) or placebo on a 1:1 allocation. All patients received standard antibiotics and supportive care. The primary outcome (overall mortality at 28 days) analysis was performed as part of an interim safety analysis and demonstrated a significantly lower mortality rate in the hydrocortisone group (6.2% vs 11.9%, p=0.006) leading to the interruption of the trial. Interestingly, the hydrocortisone group did not experience higher rates of gastrointestinal bleeding or nosocomial infections. The authors concluded that early treatment with hydrocortisone reduced 28-day mortality among patients with severe community-acquired pneumonia.
Open AccessJournal club
Community-acquired pneumonia remains a major cause of morbidity and mortality globally, with overall in-hospital mortality rates of 10%–12%, reaching 30% for patients requiring mechanical ventilation. Although corticosteroids have shown benefits in these patients, the impact on survival remains unproven. Dequin and colleagues (N Engl J Med 2023;388:1931) performed a multicentre trial in French critical care units to evaluate the effect of early hydrocortisone treatment on the mortality of patients with severe pneumonia treated in the ICU. Pneumonia severity criteria required for enrolment were: mechanical ventilation with positive end-expiratory pressure of at least 5 cmH2O; arterial oxygen tension/fractional inspired oxygen (FiO2) ratio lower than 300 (with FiO2≥50%); and Pulmonary Severity Index greater than 130. A notable exclusion criterion was septic shock. Of 5948 screened, 800 adult patients with pneumonia were randomised to either intravenous hydrocortisone (200 mg for 4 or 7 days; dependent on clinical progress followed by a tapering dose over up to 14 days) or placebo on a 1:1 allocation. All patients received standard antibiotics and supportive care. The primary outcome (overall mortality at 28 days) analysis was performed as part of an interim safety analysis and demonstrated a significantly lower mortality rate in the hydrocortisone group (6.2% vs 11.9%, p=0.006) leading to the interruption of the trial. Interestingly, the hydrocortisone group did not experience higher rates of gastrointestinal bleeding or nosocomial infections. The authors concluded that early treatment with hydrocortisone reduced 28-day mortality among patients with severe community-acquired pneumonia.
- Open Access
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 12 (3) , e17309
Renal failure and pleural effusion; a diagnostic challenge
Sjögren’s syndrome is a chronic inflammatory disorder mostly involving the exocrine glands. Extraglandular disease may occur in up to one quarter of patients. Kidney involvement is rare, more often manifested by tubular dysfunction secondary to tubulointerstitial nephritis. Primary glomerular disease is uncommon. The authors present the case of a 73-year-old woman with xerostomia and positivity for anti-Ro and anti-La antibodies admitted for acute kidney injury and exudative pleural effusion. Biopsy of salivary glands was compatible with Sjögren’s syndrome. Extraglandular involvement was also confirmed by renal and pleural deposition of AA-amyloid. The patient was started on prednisolone followed by azathioprine with rapid improvement of lung disease. However, due to progressing renal disease and clinical deterioration, prognosis was guarded and the patient died. We describe a case of secondary amyloidosis with systemic involvement and infrequent clinical manifestations, briefly reviewing the key aspects of Sjögren’s syndrome and AA-amyloidosis.
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 12 (3) , e17309
Open AccessRenal failure and pleural effusion; a diagnostic challenge
Sjögren’s syndrome is a chronic inflammatory disorder mostly involving the exocrine glands. Extraglandular disease may occur in up to one quarter of patients. Kidney involvement is rare, more often manifested by tubular dysfunction secondary to tubulointerstitial nephritis. Primary glomerular disease is uncommon. The authors present the case of a 73-year-old woman with xerostomia and positivity for anti-Ro and anti-La antibodies admitted for acute kidney injury and exudative pleural effusion. Biopsy of salivary glands was compatible with Sjögren’s syndrome. Extraglandular involvement was also confirmed by renal and pleural deposition of AA-amyloid. The patient was started on prednisolone followed by azathioprine with rapid improvement of lung disease. However, due to progressing renal disease and clinical deterioration, prognosis was guarded and the patient died. We describe a case of secondary amyloidosis with systemic involvement and infrequent clinical manifestations, briefly reviewing the key aspects of Sjögren’s syndrome and AA-amyloidosis.